Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
LIFE HEALTHCARE GROUP HOLDINGS UNSPON ADR EA REPR 4 ORD ZAR0.00
LTGHY
5
Enerpac Tool
EPAC
US Stock MarketDetailed Quotes
ASND Ascendis Pharma A/S
- 172.060
- +4.590+2.74%
Close May 2 16:00 ET
- 172.060
- 0.0000.00%
Post 16:05 ET
10.35BMarket Cap-26.23P/E (TTM)
183.000High166.960Low1.18MVolume168.000Open167.470Pre Close203.07MTurnover1.97%Turnover RatioLossP/E (Static)60.12MShares183.00052wk High-48.26P/B10.26BFloat Cap111.09052wk Low--Dividend TTM59.65MShs Float183.980Historical High--Div YieldTTM9.58%Amplitude11.920Historical Low172.768Avg Price1Lot Size
About Ascendis Pharma A/S Company
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet medical needs. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau on September 21, 2006 and is headquartered in Hellerup, Denmark.
Company Profile
SymbolASND
Company NameAscendis Pharma A/S
Listing DateJan 28, 2015
Issue Price18.00
Founded2006
CEOMr. Jan Moller Mikkelsen
MarketNASDAQ
Employees1017
Securities TypeDR
ADS Ratio1.0 : 1.0
Fiscal Year Ends12-31
AddressTuborg Boulevard 12
CityHellerup
ProvinceCapital Region
CountryDenmark
Zip Code2900
Phone45-70-22-22-44
Company Executives
- Name
- Position
- Salary
- Jan Moller Mikkelsen
- President, Chief Executive Officer and Director
- --
- Lotte Sonderbjerg
- Executive Vice President and Chief Administrative Officer
- --
- Aimee Shu
- Executive Vice President and Chief Medical Officer
- --
- Scott T Smith
- Executive Vice President and Chief Financial Officer
- --
- Michael Wolff Jensen
- Executive Vice President and Chief Legal Officer
- --
- Mads Bodenhoff
- Senior Vice President, Head of Finance and Principal Accounting Officer
- --
- Jay Donovan Wu
- Executive Vice President and U.S. President
- --
- Flemming Steen Jensen
- Executive Vice President, Product Supply and Quality
- --
- Dr. Stina Singel, M.D.
- Executive Vice President and Head of Clinical Development, Oncology
- --
- Dr. Kennett Sprogoe, PhD
- Executive Vice President and Head of Innovation and Research
- --
- Dr. Albert Cha, M.D.,PhD
- Chairman of the Board
- --
- Siham Imani
- Independent Director
- --
- Lisa Bright
- Independent Director
- --
- William Carl Fairey, Jr
- Independent Director
- --
- Lars Holtug
- Independent Director
- --
Market Insights
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
